Philippines Pharmaceuticals & Healthcare
発行: Fitch Solutions, Inc.
ページ情報: 英文 65 Pages
当レポートでは、フィリピンにおける製薬・医療産業の構造や最新動向について分析し、今後10年間の産業規模の動きを推計すると共に、業界の抱える課題 (リスク) や将来的な収益機会 (リワード) に関する評価、政府の政策・規制、競争環境、主要企業のプロファイルといった情報を盛り込んでお届けします。
Key View: This Philippines' ambition to achieve universal health coverage will be delayed by the coronavirus pandemic as much of the Department of Health's focus is currently on battling the effects of the virus. However, despite uncertainty among drug manufacturers that the signing of the maximum retail price (MRP) scheme executive order earlier in 2020 and the likelihood of negative short-term effects, the long term impact of lowering the price of innovative medicines should encourage higher volume sales and greater competition in the market, which would eventually make these planned price controls a positive for the market. After slowing during the strict March-June lockdown, the spread of Covid-19 has once again accelerated, which could lead to a further revision to pharmaceutical and healthcare spending forecasts for 2020 and beyond as the country works to recover from a steeper than expected economic recession.